Trial reportEuropean journal of clinical nutrition2017
Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.
Trial report in European journal of clinical nutrition, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Multi-omic network analysis identified betacellulin as a novel target of omega-3 fatty acid attenuation of western diet-induced nonalcoholic steatohepatitis.EMBO molecular medicine · 2023Pooled it
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2020Pooled it
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2018Pooled it
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2018Pooled it
- Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.The Journal of clinical investigation · 2020Trial
- Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism.BMJ open diabetes research & care · 2020Trial
- Trial
- Changes of the Fatty Acid Profile in Erythrocyte Membranes of Patients following 6-Month Dietary Intervention Aimed at the Regression of Nonalcoholic Fatty Liver Disease (NAFLD).Canadian journal of gastroenterology & hepatology · 2018Trial
- The omega-3 DHA induces pyroptosis and mitochondrial dysfunction in ovarian cancer cells via ROS and caspase-1 activation.Cell death discovery · 2026Article
- Transcriptomic Changes Underlying the Anti-Steatotic Effects of DHA Supplementation in Aged Obese Female Mice.International journal of molecular sciences · 2025Article
- Dietary Regulation of Hepatic Triacylglycerol Content-the Role of Eucaloric Carbohydrate Restriction with Fat or Protein Replacement.Advances in nutrition (Bethesda, Md.) · 2023Review
- Precision nutrition for targeting pathophysiology of cardiometabolic phenotypes.Reviews in endocrine & metabolic disorders · 2023Review
- The Effect of Omega-3 Fatty Acids on Insulin Resistance.Life (Basel, Switzerland) · 2023Review
- Microalgae-Sustainable Source for Alternative Proteins and Functional Ingredients Promoting Gut and Liver Health.Global challenges (Hoboken, NJ) · 2023Review
- Identification of polyunsaturated fatty acids related key modules and genes in metabolic dysfunction-associated fatty liver disease using WGCNA analysis.Frontiers in genetics · 2022Article
- B-Cell Homeostasis Is Maintained During Two Months of Head-Down Tilt Bed Rest With or Without Antioxidant Supplementation.Frontiers in immunology · 2022Article
- Integrated omics analysis reveals sirtuin signaling is central to hepatic response to a high fructose diet.BMC genomics · 2021Article
- Dietary carbohydrates and fats in nonalcoholic fatty liver disease.Nature reviews. Gastroenterology & hepatology · 2021Review
- Article
- DHA Suppresses Hepatic Lipid AccumulationFrontiers in nutrition · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND/
objectiveTreatment of subjects with non-alcoholic fatty liver disease (NAFLD) with omega-3 polyunsaturated fatty acids (FAs) suggests high levels of docosahexaenoic acid (DHA) tissue enrichment decrease liver fat content. We assessed whether changes in erythrocyte DHA enrichment (as a surrogate marker of changes in tissue enrichment) were associated with alterations in hepatic de novo lipogenesis (DNL), postprandial FA partitioning and hepatic and peripheral insulin sensitivity in a sub-study of the WELCOME trial (Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD (non-alcoholic fatty liver disease) with OMacor thErapy). SUBJECTS/
methodsSixteen participants were randomised to 4 g/day EPA+DHA (n=8) or placebo (n=8) for 15-18 months and underwent pre- and post-intervention measurements. Fasting and postprandial hepatic FA metabolism was assessed using metabolic substrates labelled with stable-isotope tracers (
resultsNine participants were stratified to DHA⩾2% (eight randomised to EPA+DHA and one to placebo) and seven to the DHA<2% group (all placebo). Compared with individuals with erythrocyte <2% change in DHA abundance, those with ⩾2% enrichment had significant improvements in hepatic insulin sensitivity, reduced fasting and postprandial plasma triglyceride concentrations, decreased fasting hepatic DNL, as well as greater appearance of
conclusionsThe findings from our pilot study indicate that individuals who achieved a change in erythrocyte DHA enrichment ⩾2% show favourable changes in hepatic FA metabolism and insulin sensitivity, which may contribute to decreasing hepatic fat content.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.